Clinical Trials with Retrovirus Mediated Gene Therapy – what Have we Learned?

ISSN： 0167-594X

Source： Journal of Neuro-Oncology, Vol.65, Iss.3, 2003-12, pp. : 227-236

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Why phase II trials in cervical chemoprevention are negative: what have we learned?

By Follen M.

Cancer Causes and Control, Vol. 13, Iss. 9, 2002-11 ,pp. : 855-873

Springer Publishing Company

Access to resources Recommend Favorite

Ionising radiation and cancer risks: What have we learned from epidemiology?

By Gilbert Ethel

International Journal of Radiation Biology, Vol. 85, Iss. 6, 2009-06 ,pp. : 467-482

Informa Healthcare

Access to resources Recommend Favorite

Borderline Resectable Pancreatic Cancer: What Have We Learned and Where Do We Go From Here?

By Katz Matthew

Annals of Surgical Oncology, Vol. 18, Iss. 3, 2011-03 ,pp. : 608-610

Springer Publishing Company

Access to resources Recommend Favorite

Tomato-based food products for prostate cancer prevention: what have we learned?

By Tan Hsueh-Li

Cancer and Metastasis Reviews, Vol. 29, Iss. 3, 2010-09 ,pp. : 553-568

Springer Publishing Company

Access to resources Recommend Favorite

Thyroid cancer pooled analysis from 14 case–control studies: what have we learned?

By Preston‐Martin Susan

Cancer Causes and Control, Vol. 14, Iss. 8, 2003-01 ,pp. : 787-789

Springer Publishing Company

Access to resources Recommend Favorite